The effects of gonadotropin releasing hormone analogue therapy on girls with gonadotropin-dependent precocious puberty

Journal of the Formosan Medical Association

Volumn 106, Issue 10, 2007, Pages 826-831

  Tung, Yi Ching ^a   Lee, Jing Sheng ^a   Tsai, Wen Yu ^a   Hsiao, Pei Hung ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Bone mineral density; GnRH analogue; Precocious puberty

Indexed keywords

GONADORELIN; GONADORELIN DERIVATIVE; GONADOTROPIN; LEUPRORELIN; TRIPTORELIN;

ARTICLE; BODY HEIGHT; BONE AGE; BONE DENSITY; BONE MINERAL; CLINICAL ARTICLE; DRUG EFFECT; DRUG WITHDRAWAL; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; INJECTION SITE DISCOMFORT; MENSTRUATION; PELVIS; PRECOCIOUS PUBERTY; SCHOOL CHILD; TAIWAN; UTERUS;

EID: 36148931395     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-6646(08)60047-9     Document Type: Article

References (24)

1. Bridges NA, Christopher JA, Hindmarsh PC, et al. Sexual precocity: sex incidence and etiology. Arch Dis Child 1994;70:116-8.
2. Dattani MT, Hindmarch PC. Normal and abnormal puberty. In: Brook C, Clayton P, Brown R, eds. Clinical Pediatric Endocrinology, 5th edition. London: Blackwell Science, 2005:183-210.
3. Sigurjonsdottir TJ, Hayles AB. Precocious puberty. Am J Dis Child 1968;115:309-21.
4. Crowley WF, Comite F, Vale W, et al. Therapeutic use of pituitary desensitization with a long-acting agonist: a potential new treatment for idiopathic precocious puberty. J Clin Endocrinol Metab 1981;52:370-2.
5. Cornea A, Janovick JA, Maya-Nunez G, et al. Gonadotropin-releasing hormone receptor microaggregation. Rate monitored by fluorescence resonance energy transfer. J Biol Chem 2001;276:2153-8.
6. Kaplan SL, Grumbach MM. Clinical Review 14: pathophysiology and treatment of sexual precocity. J Clin Endocrinol Metab 1990;71:785-9.
7. Heger S, Sippell WG, Partsch CJ. Gonadotropin-releasing hormone analogue treatment for precocious puberty: twenty years of experience. Endocr Dev 2005;8:94-125.
8. Tonini G, Lazzerini M. Side effects of GnRH analogue treatment in childhood. J Pediatr Endocrinol Metab 2000; 13(Suppl 1):795-803.
9. Manasco PK, Pescovitz OH, Feuillan PP, et al. Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty. J Clin Endocrinol Metab 1988;67:368-72.
10. Paterson WF, McNeil E, Young D, et al. Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty. Clin Endocrinol 2004;61:626-34.
11. Bertelloni S, Baroncelli GI, Sorrentino MC, et al. Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females. Eur J Pediatr 1998; 157:363-7.
12. Heger S, Partsch CJ, Sippell WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab 1999;84: 4583-90.
13. Greulich WW, Pyle SI. Radiographic Atlas of Skeletal Development of Hand and Wrist, 2nd edition. Stanford: Stanford University Press, 1959.
14. Bayley N, Pinneau SR. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr 1952;40:423-41/41:371.
15. Chen SU, Tsai WY, Lee CN, et al. Uterine and ovarian dimensions in normal Taiwanese prepubertal and postpubertal girls: an ultrasonographic study. J Med Ultrasound 1993;2:64-9.
16. Klein KO, Barnes KM, Jones JV, et al. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Heath experience. J Clin Endocrinol Metab 2001;86:4711-6.
17. Adan L, Chemaitilly W, Trivin C, et al. Factors predicting adult height in girls with idiopathic central precocious puberty: implications for treatment. Clin Endocrinol 2002; 56:297-302.
18. Boepple PA, Mansfield MJ, Wierman ME, et al. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty. Endocr Rev 1986;7:24-33.
19. Roger M, Chaussain JL, Berlier P, et al. Long term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-Trp6-luteinizing hormone-releasing hormone microcapsules. J Clin Endocrinol Metab 1986;62:670-7.
20. Gilsanz V, Roe TF, Mora S, et al. Changes in vertebral bone density in black girls and white girls during childhood and puberty. N Engl J Med 1991;325:1597-600.
21. Heaney RP, Abrams S, Dawson-Hughes B, et al. Peak bone mass. Osteoporos Int 2000;11:985-1009.
22. Matkovic V, Jelic T, Wardlaw GM, et al. Timing of peak bone mass in Caucasian females and its implication for the prevention of osteoporosis: inference from a cross-sectional model. J Clin Invest 1994;93:799-808.
23. Antoniazzi F, Zamboni G, Bertoldo F, et al. Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation. J Clin Endocrinol Metab 2003;88:1096-101.
24. Yanovski JA, Rose SR, Municchi G, et al. Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. N Engl J Med 2003;348:908-17.